Anti-Osteoprotegerin antibody produced in goat
SIGMA/O1139 - affinity isolated antibody, lyophilized powder
Synonym: Anti-OPG
MDL Number: MFCD03702437
Product Type: Chemical
This image is provided for informative purposes only and does not represent an actual product label. It should not be used as a substitute for official product labeling.
| antibody form | affinity isolated antibody |
| antibody product type | primary antibodies |
| biological source | goat |
| clone | polyclonal |
| conjugate | unconjugated |
| form | lyophilized powder |
| Quality Level | 200  |
| species reactivity | mouse |
| storage temp. | −20°C |
| target post-translational modification | unmodified |
| technique(s) | immunohistochemistry: 5-15 μg/mL |
| neutralization: suitable | |
| western blot: 0.1-0.2 μg/mL | |
| UniProt accession no. | O08712  |
| Application: | Anti-osteoprotegerin antibody may be used to neutralize mouse OPG at neutralization dose (ND50) of 0.5-2 μg/ml. The antibody is suitable for immunoblotting at a working concentration of 0.1-0.2 μg/ml. |
| Biochem/physiol Actions: | The antibody has the ability to neutralize the biological activity of recombinant mouse OPG. |
| Disclaimer: | Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals. |
| General description: | Osteoprotegerin (OPG) secreted by osteoblasts and osteogenis stromal stem cells belongs to the TNF receptor superfamily. OPG is expressed in bone marrow, osteoblasts, heart, lung, kidney, thymus, B lymphocytes, chondrocytes and smooth muscle cells. The ratio of OPG and receptor activator of NF-κB Ligand (RANKL) is crucial determining the bone mass. Receptor activator of NF-κB (RANK)/RANKL/OPG axis decides the bone biology. OPG binds RANKL and prevents the activation of osteoclasts, the cells that deplete bone mass. Excess levels of OPG lead to osteopetrosis while deficiency results in osteoporosis. The RANK/RANKL/OPG pathway mediates the activation of multiple pathways such as NF-κB, Akt, JNK, and MAPK Anti-osteoprotegerin specifically reacts with recombinant mouse OPG. The antibody may cross react with human OPG (25% homology). |
| Immunogen: | purified recombinant mouse osteoprotegerin expressed in mouse NSO cells. |
| Physical form: | Lyophilized from a 0.2 μm filtered solution in phosphate buffered saline containing carbohydrates. |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 1 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Storage Temp. | −20°C |
| UNSPSC | 51111800 |